Literature DB >> 8733984

Clinical presentation and treatment of migraine.

T L Skaer1.   

Abstract

The pathogenesis of migraine is not completely understood but may involve vasodilation of cerebral blood vessels and/or the release of vasoactive neuropeptides (ie, norepinephrine) from the perivascular axons in the dura mater after activation of the trigeminovascular system. Many environmental factors and physiologic influences may provoke a migraine or increase its severity. The typical migraine headache without aura is unilateral, pulsating, of moderate-to-severe intensity, and aggravated by physical activity. Migraine prevention is best achieved by avoidance of known migraine triggers or enhancers and by reducing the amount of lifestyle stressors. Pharmacotherapeutic options in the treatment of migraine are discussed herein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733984     DOI: 10.1016/s0149-2918(96)80004-x

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  5 in total

Review 1.  Rizatriptan: a review of its efficacy in the management of migraine.

Authors:  M Dooley; D Faulds
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 2.  Zolmitriptan: a review of its use in migraine.

Authors:  C M Spencer; N S Gunasekara; C Hills
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 3.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Precipitating and relieving factors of migraine versus tension type headache.

Authors:  Badrul Haque; Kazi Mohibur Rahman; Azharul Hoque; A T M Hasibul Hasan; Rajib Nayan Chowdhury; Sharif Uddin Khan; Mondal Badrul Alam; Mansur Habib; Quazi Deen Mohammad
Journal:  BMC Neurol       Date:  2012-08-25       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.